Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates

Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices